L. reuteri Protectis reduces pain in children with functional abdominal pain

In a newly published systematic review and meta-analysis L.reuteri Protectis (DSM 17938) was the only probiotic showing reduced pain intensity as well as an increased number of pain free days compared to placebo, in children with functional abdominal pain (FAP). 

Even if functional abdominal pain is a common gastrointestinal disorder, there are still no adequate treatment options available. The aim of the systematic review and meta-analysis was therefore to evaluate strain-specific probiotic effects on functional abdominal pain in children.

The meta-analysis included nine studies, of which six were conducted with L. reuteri DSM 17938 and three with L. rhamnosus GG (LGG). The primary outcome, number of children with no symptoms at end of intervention, was however not reached.

“As the primary outcome was not reached, no firm conclusions can be drawn from our meta-analysis. Still, we can conclude that L. reuteri DSM 17938 can be effective in reducing pain intensity and increasing number of days without pain in children suffering from functional abdominal pain,” says the principal investigator of the study, Assist. Professor Iva Hojsak at the Children's Hospital Zagreb in Croatia.

The meta-analysis found no significant benefit of supplementation of LGG compared to placebo in children with functional abdominal pain.

“The result from this meta-analysis shows the potential of L. reuteri DSM 17938 in the management of children suffering from functional abdominal pain. It is of value for both patients and healthcare professionals that these positive effects have now been confirmed in a well-performed systematic review and meta-analysis,” says Isabelle Ducellier, CEO of BioGaia.

The systematic review and meta-analysis was published online 17 September 2020 in European Journal of Pediatrics. Study details are found here.

 

Latest press releases from BioGaia
10.10.2020 BioGaia’s Board makes decision regarding extra dividend
13.08.2020 BioGaia Interim report January – June 2020
08.05.2020 Annual General Meeting of BioGaia

For additional information please contact
Isabelle Ducellier, Managing Director, telephone: +46 8 555 293 00

BioGaia is an innovative Swedish healthcare company that develops, markets and sells probiotic products with documented health benefits. The products are sold through local distribution partners in more than 100 countries worldwide. The class B share of the Parent Company BioGaia AB is quoted on the Mid Cap segment of Nasdaq Stockholm. www.biogaia.com

About Us

BioGaia is a healthcare company that develops, markets and sells probiotic products with documented health benefits. The products are primarily based on the lactic acid bacterium Lactobacillus reuteri, which has probiotic, health-enhancing effects. The class B share of the Parent Company BioGaia AB is quoted on the Mid Cap list of the NASDAQ OMX Nordic Exchange Stockholm. www.biogaia.com If you need more information about BioGaia and our products please visit our website or download our press kit from: http://www.biogaia.com/press-material

Subscribe

Quotes

The result from this meta-analysis shows the potential of L. reuteri DSM 17938 in the management of children suffering from functional abdominal pain. It is of value for both patients and healthcare professionals that these positive effects have now been confirmed in a well-performed systematic review and meta-analysis
Isabelle Ducellier, CEO of BioGaia